These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27781308)

  • 21. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of polytetrafluoroethylene-covered stents implanted during percutaneous coronary intervention for management of acute coronary perforation.
    Copeland KA; Hopkins JT; Weintraub WS; Rahman E
    Catheter Cardiovasc Interv; 2012 Jul; 80(1):53-7. PubMed ID: 21953680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term follow-up of "full metal jacket" of de novo coronary lesions with new generation Zotarolimus-eluting stents.
    Durante A; Foglia Manzillo G; Burzotta F; Trani C; Aurigemma C; Summaria F; Patrizi R; Talarico GP; Latib A; Figini F; Romagnoli E; De Vita M; Fantoni C; My L; Larosa C; Manzoli A; Turturo M; Berni A; Corrado G
    Int J Cardiol; 2016 Oct; 221():1008-12. PubMed ID: 27441483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine angiographic follow-up versus clinical follow-up in patients with multivessel coronary artery diseases following percutaneous coronary intervention with drug-eluting stents: a nested case-control study within a Korean population.
    Kim YH; Her AY; Rha SW; Choi BG; Shim M; Choi SY; Byun JK; Li H; Kim W; Kang JH; Choi JY; Park EJ; Park SH; Lee S; Na JO; Choi CU; Lim HE; Kim EJ; Park CG; Seo HS; Oh DJ
    Coron Artery Dis; 2017 Jun; 28(4):307-314. PubMed ID: 28272162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
    Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
    Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year clinical outcomes after sirolimus-eluting stent implantation: Impact of an in-stent restenosis target lesion.
    Miura K; Kadota K; Habara S; Miyawaki H; Shimada T; Ohya M; Amano H; Izawa Y; Hyodo Y; Otsuru S; Hasegawa D; Tada T; Tanaka H; Fuku Y; Goto T; Mitsudo K
    Am Heart J; 2016 May; 175():47-55. PubMed ID: 27179723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. If worst comes to horrible - sealing an iatrogenic coronary perforation with a polytetrafluoroethylene-covered stent in a patient with aspirin intolerance.
    Viertel A; Andreas D; Grönefeld G
    Eur Heart J Acute Cardiovasc Care; 2020 Aug; 9(5):NP3-NP4. PubMed ID: 26865577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcomes of Different Two-Stent Techniques With Second-Generation Drug-Eluting Stents for Unprotected Left Main Bifurcation Disease: Insights From the FAILS-2 Study.
    Pavani M; Conrotto F; Cerrato E; D'Ascenzo F; Kawamoto H; Núñez-Gil IJ; Pennone M; Garbo R; Tomassini F; Colombo F; Scacciatella P; Varbella F; Chieffo A; Colombo A; Escaned J
    J Invasive Cardiol; 2018 Aug; 30(8):276-281. PubMed ID: 30068784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unprotected Left Main Coronary Artery Disease: Outcomes of Treatment With Second-Generation Drug-Eluting Stents - Insight From the FAILS-2 Study.
    Barbero U; Kanji R; Cerrato E; Di Summa R; Conrotto F; Kawamoto H; Biondi-Zoccai G; Gili S; Ugo F; Iannaccone M; Gagliardi M; De Benedictis M; Doronzo B; Varbella F; D'Amico M; Moretti C; Colombo A; Escaned J; D'Ascenzo F
    J Invasive Cardiol; 2018 Aug; 30(8):283-288. PubMed ID: 29760284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
    Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.
    Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Yamaji K; Ando K; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Kato M; Suwa S; Takizawa A; Takatsu Y; Shinoda E; Eizawa H; Takeda T; Lee JD; Inoko M; Ogawa H; Hamasaki S; Horie M; Nohara R; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
    Circ Cardiovasc Interv; 2014 Apr; 7(2):168-79. PubMed ID: 24550439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.